0.2 ML ocriplasmin 2.5 MG/ML Injection

Known as: ocriplasmin 0.5 MG in 0.2 ML Injection, OCRIPLASMIN 0.5MG/0.2ML OPH INJ, OCRIPLASMIN 0.5MG/0.2ML INJ,OPH [VA Product] 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2014-2018
0120142018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
PURPOSE To investigate predictors of success, visual outcomes, and complications of intravitreal ocriplasmin for the treatment of… (More)
Is this relevant?
Review
2016
Review
2016
Die Behandlung einer vitreomakulären Traktion (VMT) mit Ocriplasmin (Jetrea®) war in großen Phase-3-Studien wirksam. Wir… (More)
Is this relevant?
2015
2015
Die Behandlung einer vitreomakulären Traktion (VMT) mit Ocriplasmin (Jetrea®) war in großen Phase-3-Studien wirksam, und dieses… (More)
Is this relevant?
2015
2015
Es wird über den Fall einer 50-jährigen Patientin berichtet, die bei fokaler vitreomakulärer Traktion und Visus von 0,8 p sowie… (More)
Is this relevant?
2015
2015
PURPOSE To present the long-term follow-up of a patient injected with intravitreal ocriplasmin who experienced severe acute post… (More)
Is this relevant?
2015
2015
Intravitreal ocriplasmin was recently approved by the Food and Drug Administration to achieve medical vitreolysis in the setting… (More)
Is this relevant?
Review
2015
Review
2015
PURPOSE To report initial experience with intravitreal ocriplasmin (IVO) and to describe outer retina reflectivity changes… (More)
Is this relevant?
2014
2014
Vitreomacular traction and vitreomacular traction with macular hole are conditions associated with visual disturbance and… (More)
  • figure 1
  • figure 3
  • figure 4
  • figure 2
Is this relevant?